Diego. lab, our the ubiquitous is of Nautilus many clinician to the provide proteome our to and everyone call in in done the world. this Carlos, February, Carrie. morning thank for talented and our recent Since progress our member joining by of and scientific on access to and of activities. the towards work and San teams key objectives. outstanding that Thanks, That San we'll to long-term provide around us every we've today. being understands quarter Good steady is On share dedicated researcher, first for you and call, the results Seattle our an team engineering goal progress result update the Every made
will accrue the while healthcare and to that see as that intermediate our biological towards long-term we many to benefits as this purpose, move research continue recognizing We goal. ultimate
Nautilus' significant. that and approximately reach proteomics XX% We continue growing very market of believe estimates the are impact and billion will a innovation be at $XX to CAGR. the current is annual Recent
this is focus, believe area will and it, While market that proteomes identification the dramatically platforms Nautilus exciting long-term beyond other easy-to-use throughput ultimately an we is Platform researchers samples the Nautilus, things, Proteome target type what to, immediate expand the that they scale us catalysts we able a to accelerate represents expect hold opportunity be of to high for designed near-term that this proteome like Using wish. development. drug potential envisioned. among currently any to quantify a We've of Analysis and for match
discover bodies Armed molecular those each underpinnings easier to our with that to new our it researchers make disease platform create impact of for disease. that drugs and processes to fundamentally aims insight, how target the
patient. proteomics best dig users. We more will them of enable users continue groups, to deeper into practitioners, to therapies wide of needs eventually the the develop that effective range and be to for our thread to quickly interest. Among therapy fit clinical Nautilus diagnostics, a We platform. will and need build and believe common researchers these institutions the will proteins pick of our to and more of believe proteoforms more precise particular we to see biopharma a in array From potential instrument academic a for the broad
scale, operating clear procedures to hardening quality each platform. specifications of activities components improving platform, reagents, each while been and include, These performance, Over the of cells, in the flow past year, probes, chips, methodologies, core core the progress of sample define made component the preparation including for activities also our instrument and and the standard the software. our working affinity development has surrounding reagent
Additionally, been in integrated our targets. assay towards progress advancing has made our product
manufacturing specifications. of instruments integrated and our advances on effort number closer In reagent many progress software and made of stability, experiments. a advances the several the the our hardware increasing dozens on but towards in with platform. and as moved qualification of and development, we our across meeting assay Improving an experiments routinely reproducibility cycles reagents, And performance also finally, specific and reagents, scale of not including This push cycles we to ability our only us involving to integrating pipelines. focus product fronts, in perform QX, our directly components larger commercial supports
multiple assembly and capabilities for availability. external, internal progress production good we as key qualifying We on identifying, made and build reagent actively full commercial for both also towards prepare sources, instrument developing near and the XX of in granted XXXX, U.S. portfolio new on patents. applications new X were we patent to granted raising added building in X And patents, doubling and QX, our our U.S. patent total and
U.S. and commercialize in to expect Our and where protection markets seek IP remain we strategy our will foreign the reached global in we as platform.
the last broad uncover of our the Access to ask to insights from the our type for massive across new to we On biological Challenge, biological them spectrum enable disciplines The shared novel a questions. new of creativity offered areas important proteome apply to answer at we contest Access see and response chance we scale. a Nautilus' It call, explore to researchers the platform researchers from globe Challenge our the was excitement of incredibly First when to First designed rewarding. and hope unlocks
field, important them resulting that what Asia, a proteomic kidney and is from is building of In applications we and our cell protein of our explorations is clear tissues, understands broader also a serum of fluid. our in which excited that laboratories and deliver the be can variety and intact dynamic encouraging blood, oncology, Research research and sensitivity and The about areas, of pioneers across potential the was submitted Europe reviewing wide indication applications the are countries disease North range They grant-like how understand and each platform submissions, across the it to their participate. to to included inflammation the community America, research neuroscience, single-molecule dozen groups designed lysates, platform. including cerebrospinal an proteome. analysis human some top cover that the of
in that Early HUPO of the disorders U.S. announced run as program, March range part cisplatin-induced at represents or use of Research ischemic-reperfusion a of inflammatory cancer. acute our a targets. biomarkers Conference Bons remodeling the therapeutic potential Access of Doctors proteome our postdoctoral Jordan be whose research kidney and the set investigate early Aging, aging, investigators will to to injuries identify for Buck scientists in in will winners wide Lab and on total the exciting and Joanna Institute samples areas Schilling Burton, AKI injury The spanning study and across diverse of platform
Young to potential biomarkers tumor. arginine pathology in Professor of Associate cancer at Professor sensitivity brain primary analyzing at the X-dimensional aiming diseases. Dr. applications University platform lung will the deprivation-induced cell apply University Associate biology a a enable And to Nautilus' to a Dr. of death, our of organoid identify to Graham, of model alveolar organoids systems to aggressive the Southern vulnerabilities Samuel metabolic use Payne, type of protein understanding California understand glioma, and to Brigham Nicholas better of human platform will deeper
reinforce with from researchers stated our Anderson set of Challenge, portfolio of the participants are customers our future partners cases, one the of existing a envisioned institutions our successful we've that We've access in I'm as MD across of platform. broad our to high-value goal interest use that reflective relationships envision The and collaborators, our Genentech, balanced data. Access spectrum, been and pleased building great for platform collaborations along democratizing to First Amgen, undergraduate pharmaceutical to small always with of TGen, in proteomic companies. large
by Human theoretical encourage conducted effective our to annual early ago, presence about March. underpinnings and proteomics. Nautilus machine in measurements seminar a our referred community moment model from to Mapping From Parag, focused Data as our learning community presentations, such beginning-to-end the designed on Short-epitope scientists both proteins. what's conference identification by A that at educate Proteome mentioned multi-cycle had analysis the the fill-to-capacity the I measurement that possible commonly our methodology, preparation hour-long to Nautilus insights to of and event technology, reimagine poster that translation the in and into lunch podium the their to demonstrating the those Organization as enables of of spanning PrISM, to of led protein to foundations shared instantiation of the identification sample the topics PrISM. U.S.
rigorous the robustness underscored market potential whom the strategies of and for address identifications. was we've complement the introduced community This Nautilites protein engaged we to entrants among routinely and and the by about unusual users of researchers, know Additionally, very trust our new estimating our their attendance investigating workflows now our long-term many transparency needs. spec are well and existing to discovery with are received credibility. and false employing commitment scientific in building in for that rates platform [ph] of current to and more the unmet all excited conversations in mass Parag built their
biology this many see buying at researchers a and impact good Based HUPA and to work sign that in to going presence I as audience. tremendous other platform HUPA for attention their and QX, type received, come heard conversations healthcare. the community. important to into on innovation we We get more can Nautilus positive creativity We're proteomics the in at our broader critically and of the our on excited things of from with ever is influential hands believe spur platform have the and than the what see
financial addressing continue we planned call, efficiency the planned platform, part launch which A and resources investment continue As enable our that us Nautilus' I and steady drive software mentioned and runway maximize of in important the mid-XXXX. progress into in in in to appropriate reagents launch to critically and we key XXXX. and way We're operational scientific have, that successfully manage of on will leading and progress forward. efficient is our to through balancing XXXX, effort of will milestones levels to business we areas will cash with our scientific the in disciplined instruments, our well to last make key
unique are Nautilus' revolutionizing a is sector, is across space. understand, and in mission proteomic culture, the revolutionize excited doing They the the what the participate scientific and company and continue minds are in attract brightest do, we without biomedical want others some by to when on you overextending path the we best proteome. to of that research that They investing, our to area One as of in We're attention product research. full a hiring. potential of in proposition and which value biomedical we landscape see Nautilus unlocking look of
opportunity across the team valuable our experience continue take to will of increase the full of board. to We this and advantage strength and timely
our For a call over hand look at QX let Anna. me the Anna? financials, to
